Condition
|
Expected gain (number prevented) under original assumptions
|
Expected gain (number prevented) applying efficacy rates from Lasbela baseline surveyb
|
---|
Diarrhoea
|
277 per thousand
|
30 per thousand
|
Bronchopneumonia
|
61 per thousand
|
7 per thousand
|
Blindness
|
27 per thousand
|
3 per thousand
|
Otitis media
|
25 per thousand
|
3 per thousand
|
Death
|
14 per thousand
|
15 per ten thousand
|
Convulsions
|
3 per thousand
|
3 per ten thousand
|
Post-infectious
|
4 per ten thousand
|
5 per hundred thousand
|
encephalitis
|
7 per million
|
7 per ten million
|
SSPE
|
Losses (original assumptions)
|
Losses after baseline survey
|
Anaphylaxis
|
7 per ten million
|
7 per hundred million
|
- a Sources for all calculations are the same as in Table 1. Differences in gains are due to revised assumptions following the baseline survey.
- b Gain = [RDx(PRIxVER)] × 0.361, where RD = Risk difference, PRI = proportion requiring intervention (0.49), and VER = Vaccine efficacy rate (0.415).
- The bold-font rows show the conditions for which the data are most applicable to the South Asia region or, at least, developing country conditions - diarrhoea, pneumonia, blindness and death.